Reports Q3 revenue $16.3M, consensus $15.63M. “We delivered an outstanding Q3, highlighted by 37% year-over-year constant currency ex. COVID-19 revenue growth. Our growth came across the breadth of our portfolio areas and geographies, despite the currently challenging macro environment. Our strong performance was complemented by continued improvements to gross margins and operating expenses, including a marked 39% improvement in year-over-year adjusted operating loss and a significant reduction in our cash burn.” said Jurgi Camblong, CEO. “The team at SOPHiA GENETICS continues to drive innovation and growth in the area of technology-agnostic artificial intelligence software for genomic and multimodal analysis, and the recurring nature of our revenues positions us well to weather economic uncertainty, as we finish this year and look ahead to 2024.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SOPH:
- SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2023
- SOPHiA GENETICS to Announce Financial Results for the Third Quarter of Fiscal 2023 on November 7, 2023
- Sophia Genetics announces collaboration with MSK Cancer Center and AstraZeneca
- Sophia Genetics management to meet virtually with BTIG
- Laboratorio Curie expands relationship with SOPHiA GENETICS